Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation
After 2 years of follow-up in a randomized trial involving 301 patients with moderate ischemic mitral regurgitation undergoing CABG, the addition of mitral-valve repair did not improve left ventricular function or remodeling. Ischemic mitral regurgitation of moderate severity develops in approximate...
Saved in:
Published in: | The New England journal of medicine Vol. 374; no. 20; pp. 1932 - 1941 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Massachusetts Medical Society
19-05-2016
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | After 2 years of follow-up in a randomized trial involving 301 patients with moderate ischemic mitral regurgitation undergoing CABG, the addition of mitral-valve repair did not improve left ventricular function or remodeling.
Ischemic mitral regurgitation of moderate severity develops in approximately 10% of patients after myocardial infarction.
1
,
2
Mitral regurgitation is caused by the displacement of papillary muscle, leaflet tethering, reduced closing forces, and annular dilatation. Over time, the condition has an adverse effect on the rate of survival free of heart failure.
3
Because most patients with ischemic mitral regurgitation have multivessel coronary artery disease requiring revascularization, surgeons have to consider whether to add mitral-valve repair to coronary-artery bypass grafting (CABG).
The appropriate surgical management of moderate ischemic mitral regurgitation at the time of CABG remains controversial. Some experts advocate revascularization alone . . . |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 Drs. Michler and Smith contributed equally to this article. A list of members of the Cardiothoracic Surgical Trials Network (CTSN) is provided in the Supplementary Appendix, available at NEJM.org |
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa1602003 |